USPSTF Releases Final Recommendations on Use of Breast Cancer Prevention Drugs

Wednesday, September 25, 2013

The US Preventive Services Task Force has recommended that breast cancer primary prevention drugs be offered to higher-risk women at low risk of side effects.

Memorial Sloan Kettering’s Chief of Breast Cancer Medicine, Clifford Hudis, is available to discuss the recommendations, how they align with the recommendations of other cancer organizations, and the way the guidelines might play out in the clinic with patients.


For more information and to set up an interview, contact the Media Staff.

Add new comment

We welcome your questions and comments. While we share many of them with our world-class doctors and researchers, we regret that in order to protect your privacy, we are not able to make personal medical recommendations on this forum, nor do we publish comments that contain your personal information. If you would like to consult with an MSK doctor, we encourage you to make an appointment at 800-525-2225 or request an appointment online.

Your email address is kept private and will not be shown publicly.